CIMT 2018 Annual Meeting

Location: Mainz, Germany 15.05.2018 – 17.05.2018 Conference Webpage “Every year, the CIMT Annual Meeting connects the global cancer immunotherapy community in the heart of Europe. As the largest meeting focused on cancer immunotherapy research and development in Europe, CIMT 2018 invites international participants for high-level scientific exchange, collaboration, and education focused on cancer immunotherapy.” (Citation: Conference Webpage)

Qualified Person – Symposium & Workshop

Location: Cologne, Germany 14.05.2018– 16.05.2018 apceth will present at this event! “Update 2018 – Status quo zu Änderungen, Umsetzung und Herausforderungen: • Aktuelles zu Annex 16 und 17 und Umsetzung der regulatorischen Rahmenbedingungen • Anforderungen zur Vorbereitung auf Audits und Inspektionen • Update rund um die Sicherheitsmerkmale gemäß EU Falsified Medicines Directive • Konsequenzen aus dem MRA-Abkommen im GMP-Bereich • Auswirkungen des neuen Stand-alone GMP-Leitfadens für ATMPs” Source: Conference Webpage

XPOMET© Convention

Location: Leipzig, Germany 21.03.2018 – 23.03.2018 Conference Webpage XPOMET© Convention “ is the first and only event of its kind – it combines interdisciplinary networking, high-profile keynotes, progressive projects and discussion impulses as well as innovative and interactive formats to create a three-day tribute to technology, progress and the further development of medicine. “ (Citation: Conference Webpage)

Sachs BioCapital USA Forum

Location: New York, NY 21.03.2018 apceth will present at this event! Conference Webpage “The BCUSA showcases biotechs with advanced therapeutics and brings them together with pharma partnering executives and institutional investors, bankers and advisers. The programme features panels on pharma-biotech dealmaking, advances in different therapeutics areas and a keynote and roundtable on investment.” (Citation: Conference Webpage)

BIO-Europe Spring

Location: Amsterdam, The Netherlands 12.03.2018 – 14.03.2018 Conference Webpage “With a focus on European innovation and global collaboration, BIO-Europe Spring is the premier springtime partnering conference bringing together a “whoʼs who” from biotech, pharma and finance in the most innovative biopharma clusters in Europe.” (Citation: Conference Webpage)

EHA-SWG Scientific Meeting on Shaping the Future of Mesenchymal Stromal Cells Therapy

Location: Amsterdam, The Netherlands 23.11.2017 – 25.11.2017 Conference Webpage See more information on apceth as invited speaker at this conference: Download Press Release_EHA-SWG Meeting “The SWG Meeting “Shaping the future of MSC therapy” will be unique in bringing together basic science, as well as translational and clinical research. The meeting will cover the biology of tissue homeostasis, including the role of MSC in tissue repair and immune modulatory mechanisms underlying treatment response. It will also address translational hurdles in the area of product development, including potency assay development. Finally, the meeting will deal with the international regulatory landscape, the role of biotech and academia, in the context of clinical trials,” (Citation: Conference Webpage)

apceth Biopharma to Present at EHA-SWG Scientific Meeting

apceth Biopharma is proud to announce that it will be presenting its latest results on apceth-201 in graft-vs-host-disease (GvHD) during the European Hematology Society (EHA)-SWG Scientific Meeting in Amsterdam on November 23-25, 2017. apceth’s presentation will take place on November 24, 2017 between 16:00 – 17:00. For more information, please consult the full press release. Download Press Release_EHA-SWG Meeting Please note: today apceth Biopharma focuses solely on the CDMO business

Phacilitate Cell and Gene Therapy World 2018

Location: Miami, FL/USA 22.01.2018 – 25.01.2018 apceth’s Senior Management will  give a talk and participate in a panel discussion at this conference. Conference Webpage „The world’s only whole-ecosystem partnering event for the cell & gene therapy industry.” (Citation: Conference Webpage)

New peer-reviewed publication with the results of apceth Biopharma’s TREAT-ME 1 clinical trial

This phase I/II, first-in-class, first-in-men clinical trial tested safety, tolerability and efficacy of genetically modified mesenchymal stem cells (MSC) in the treatment of advanced, recurrent gastrointestinal cancer. Download publication: Publication_apceth Biopharma_TREAT-ME 1 clinical trial Please note: today apceth Biopharma focuses solely on the CDMO business